



Docket No.: PF-0233-1 DIV

Response Under 37 C.F.R. 1.116 - Expedited Procedure

Examining Group 1643

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box AF, Washington, D.C. 20231 on January 18, 2002.

By: Margaret M. Hasson Printed: Margaret M. Hasson

COPY OF PAPERS  
ORIGINALLY FILED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Goli et al.

Title: NOVEL HUMAN CYTOKINE/STEROID RECEPTOR PROTEIN

Serial No.: 09/203,548 Filing Date: December 01, 1998

Examiner: Pak, M. Group Art Unit: 1643 **RECEIVED**

Box AF  
Commissioner for Patents  
Washington, D.C. 20231

MAR 04 2002

TECH CENTER 1600/2900

**RESPONSE TO NOTIFICATION OF NON-COMPLIANCE WITH 37 CFR 1.192(c)**

Sir:

This is in response to the Notification of Non-Compliance with 37 CFR 1.192(c) mailed December 18, 2001, in the above-referenced application.

The Examiner has asserted that the Appeal Brief for the above-referenced application is defective because it allegedly does not contain a concise explanation of the claimed invention, referring to the specification by page and line number. Specifically, the Examiner asserts that the sequence comparison mentioned in the Summary of the Invention is not found in the specification.

Appellants note that the sequence comparisons between the claimed CYSTAR polypeptide both and rat 25-Dx protein and porcine steroid membrane binding protein are found in the specification at page 12, lines 25-26. The last line of the first paragraph of the Summary directs the Board's attention to the specification at page 12, lines 21-29, which lines contain the sequence comparisons as well as other structural information regarding the CYSTAR polypeptide. Nonetheless, Appellants submit herein three copies of a new Appeal Brief, in which the separate elements of the Summary of the Invention, including the sequence comparisons, are each provided

with references to the specification by page and line number. No other changes have been made to the Appeal Brief. Appellants believe that this Appeal Brief is fully in compliance with 37 CFR 1.192(c).

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. **09-0108.**

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: January 18, 2002

Barrie Greene

Barrie Greene

Reg. No. 46,740

Direct Dial Telephone: (650) 621-7576

Date: 18 January 2002

Diana Hamlet-Cox

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 621-4639

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886